Tradestie Institutional Equity Comparison Engine

NIVF vs GCL โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

GCL Overall Edge

GCL Captures Institutional Edge (2โ€“0 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to GCL Global Holdings Ltd Ordinary Shares (GCL) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, NIVF trades at N/M Forward P/E with -238.2% operating margin (-4.7% YoY revenue) versus GCL at N/M Forward P/E and -5.5% operating margin (+53.8% YoY). In options structure, NIVF sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against GCL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
NIVF N/M vs GCL N/M Fwd P/E
Growth & Margin Winner GCL
Op Margin -238.2% vs -5.5% ยท YoY -4.7% vs +53.8%
Momentum & Technical Winner GCL
1Y -44.8% vs -28.4% ยท 52W Pos 5% vs 57%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
NIVF NASDAQ
NewGenIvf Group Limited Class A ordinary shares
Services-Misc Health & Allied Services, Nec
$0.20
-11.33% 1D
Market Cap $369,508
1M Return -26.52%
1Y Return -44.83%
Forward P/E N/M
Unified AI Score
45.8 / 100 HOLD
Tech 50.0 Fund 44.0 Flow 50.0 Mom 45.0
GCL NASDAQ
GCL Global Holdings Ltd Ordinary Shares
Services-Prepackaged Software
$1.16
-2.93% 1D
Market Cap $153.0M
1M Return +33.16%
1Y Return -28.4%
Forward P/E N/M
Unified AI Score
31.6 / 100 SELL
Tech 50.0 Fund 33.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NIVF -44.83% GCL -28.4% Spread: +16.43 pp (GCL Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
NIVF TTM Op. Margin: -238.2% GCL TTM Op. Margin: -5.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NIVF vs GCL. Trailing 12-month operating profitability (NIVF -238.2% vs GCL -5.5%) and valuation multiples (NIVF N/M vs GCL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NIVF (3) vs GCL (5)
Institutional Metric NIVF GCL Criterion Row Winner
Market Capitalization Scale $369,508 $153.0M Larger Scale GCL
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -4.7% +53.8% Higher Growth GCL
Operating Margin (TTM) Profitability -238.2% -5.5% Higher Margin GCL
Net Profit Margin Profitability 24.2% -10.5% Higher Margin NIVF
Return on Equity (ROE) Capital Efficiency 5.5% -67.3% Higher ROE NIVF
52-Week Range Position Momentum 5% ($0โ€“$3) 57% ($0โ€“$2) Stronger Trend GCL
Beta / 30D Volatility Risk Regime 0.07ฮฒ ยท 3093% Vol 1.52ฮฒ ยท 75% Vol Lower Realized Risk GCL
Unified Institutional Score Composite Signal 45.8 / 100 (HOLD) 31.6 / 100 (SELL) Higher Composite NIVF

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NIVF vs GCL Buy Guide
NIVF UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live NIVF Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
GCL UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live GCL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NIVF nor GCL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.